Show simple item record

dc.contributor.authorGoswami, Pushpendra
dc.contributor.authorOliva, Esther
dc.contributor.authorIonova, Tatyana
dc.contributor.authorElse, R
dc.contributor.authorKell, J
dc.contributor.authorFielding, AK
dc.contributor.authorJennings, DM
dc.contributor.authorKarakantza , M
dc.contributor.authorAl-Ismail, S
dc.contributor.authorCollins, GP
dc.contributor.authorMcConnell , S
dc.contributor.authorLangton, Catherine
dc.contributor.authorSalek, Sam
dc.date.accessioned2020-03-31T00:08:03Z
dc.date.available2020-03-31T00:08:03Z
dc.date.issued2020-03-05
dc.identifier.citationGoswami , P , Oliva , E , Ionova , T , Else , R , Kell , J , Fielding , AK , Jennings , DM , Karakantza , M , Al-Ismail , S , Collins , GP , McConnell , S , Langton , C & Salek , S 2020 , ' Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO) : Content Validity ' , Frontiers in Pharmacology , vol. 11 , 209 , pp. 209 . https://doi.org/10.3389/fphar.2020.00209
dc.identifier.issn1663-9812
dc.identifier.otherPURE: 19383376
dc.identifier.otherPURE UUID: d8e1a609-2a9b-49d0-99a1-d159c6941722
dc.identifier.otherPubMed: 32210809
dc.identifier.otherScopus: 85082678241
dc.identifier.urihttp://hdl.handle.net/2299/22532
dc.descriptionCopyright © 2020 Goswami, Oliva, Ionova, Else, Kell, Fielding, Jennings, Karakantza, Al-Ismail, Collins, McConnell, Langton and Salek.
dc.description.abstractBackground: The quality of life of patients at all stages of hematological malignancy is greatly affected by the disease and its treatment. There is a wide range of health-related quality of life (HRQoL) issues important to these patients. Any new instrument developed to measure HRQoL of such patients should be content valid, i.e., the items should be comprehensively relevant to the patients and their health condition. The aim of the present study was to examine content validity of a hematological malignancy specific patient reported outcome measure (HM-PRO) developed for use in routine clinical practice. Methods: Following literature review and semi-structured interviews, the generated themes and sub-themes were discussed to develop the prototype version of the HM-PRO. A 4-step approach was used for content validation: initial testing and cognitive interviewing; item rating; content validity panel meeting; final field testing and cognitive interviewing. Additional questions related to patients' perception of recall period and preferred sentence structure (i.e., question or statement) of the items were also asked during cognitive interviews. Results: The content analysis of 129 transcribed semi-structured interviews resulted in the prototype version of the instrument consisting of 58 items grouped into two parts: Part A (impact/HRQoL - 34 items) and Part B (signs and symptoms - 24 items). The initial testing showed intra-class correlation coefficient (ICC) of >0.8 for both Part A and Part B. Item rating for language clarity, completeness, relevance, and response scale by experts and patients showed content validity index for scales average >0.8 for both Part A and Part B, except 0.64 for relevance for Part A by the patient panel. The final testing of the revised version of the instrument showed the Cronbach's alpha value of 0.91 for Part A and 0.76 for Part B, suggesting high internal consistency, and ICC of 0.91 for Part A and 0.76 for Part B. The recall period of "today" for Part-A and "last 3 days" for Part-B were the patients' preferred "recall period." Furthermore, the patients expressed preference to the HM-PRO items as statements. Conclusion: The findings of this study confirm that the HM-PRO possesses a strong content validity, includes all the issues important to patients and is easy to read, understand and respond to spontaneously.en
dc.language.isoeng
dc.relation.ispartofFrontiers in Pharmacology
dc.subjectHM-PRO
dc.subjectclinical practice
dc.subjectclinical research
dc.subjectcontent validity
dc.subjecthematological malignancy
dc.subjectquality of life
dc.subjectsymptoms
dc.subjectPharmacology
dc.subjectPharmacology (medical)
dc.titleDevelopment of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO) : Content Validityen
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPublic Health and Patient Safety Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85082678241&partnerID=8YFLogxK
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.3389/fphar.2020.00209
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record